Source:http://linkedlifedata.com/resource/pubmed/id/14633670
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
2003-11-24
|
pubmed:abstractText |
Human CYP2A6 has been recognized as being involved in the mutagenic activation of promutagens such as the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Methoxsalen (8-methoxypsoralen) was reported to inhibit CYP2A6. In the present study, the inhibitory effects of methoxsalen on NNK-induced lung tumorigenesis in female A/J mice were examined. Female A/J mice were treated with methoxsalen at doses of 50 or 12.5 mg/kg body weight, given by stomach tube, daily for 3 days. One h after the final treatment, NNK was injected i.p. at a dose of 2 mg/mouse. The experiments were terminated 16 weeks after the first methoxsalen treatment, and lung adenomas were analyzed. Pretreatment of methoxsalen significantly reduced tumor incidence from 93.8% to 16.7% (50 mg/kg) and 20.0% (12.5 mg/kg), and tumor multiplicity from 5.97 to 0.23 (50 mg/kg) and 0.25 (12.5 mg/kg) tumors/mouse. These results clearly demonstrated that methoxsalen, a potent human CYP2A6 inhibitor, is a strong chemopreventive agent against NNK-induction of lung tumorigenesis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-(N-methyl-N-nitrosamino)-1-(3-pyri...,
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinogens,
http://linkedlifedata.com/resource/pubmed/chemical/Methoxsalen,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrosamines,
http://linkedlifedata.com/resource/pubmed/chemical/coumarin 7-hydroxylase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
7581-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14633670-Animals,
pubmed-meshheading:14633670-Anticarcinogenic Agents,
pubmed-meshheading:14633670-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:14633670-Carcinogens,
pubmed-meshheading:14633670-Female,
pubmed-meshheading:14633670-Lung Neoplasms,
pubmed-meshheading:14633670-Methoxsalen,
pubmed-meshheading:14633670-Mice,
pubmed-meshheading:14633670-Mice, Inbred A,
pubmed-meshheading:14633670-Mixed Function Oxygenases,
pubmed-meshheading:14633670-Nitrosamines
|
pubmed:year |
2003
|
pubmed:articleTitle |
Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
|
pubmed:affiliation |
Onco-Pathology, Department of Pathology and Host-Defense, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|